AR101185A1 - Anticuerpos anti-factor v o factor v activado - Google Patents
Anticuerpos anti-factor v o factor v activadoInfo
- Publication number
- AR101185A1 AR101185A1 ARP150102212A ARP150102212A AR101185A1 AR 101185 A1 AR101185 A1 AR 101185A1 AR P150102212 A ARP150102212 A AR P150102212A AR P150102212 A ARP150102212 A AR P150102212A AR 101185 A1 AR101185 A1 AR 101185A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- factor
- fva
- variable regions
- activated antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente solicitud se relaciona con anticuerpos monoclonales o fragmentos de estos, que específicamente se unen al Factor V activado (FVa), que despliegan un efecto pro-coagulante y usos terapéuticos de estos. Reivindicación 10: Un anticuerpo monoclonal anti-FVa o un fragmento de este de unión al antígeno, donde las CDR de las regiones variables de cadena ligera y pesada son como en las regiones variables definidas por la SEQ ID Nº 1 y SEQ ID Nº 2, SEQ ID Nº 3 y SEQ ID Nº 4, SEQ ID Nº 5 y SEQ ID Nº 6, SEQ ID Nº 7 y SEQ ID Nº 8, SEQ ID Nº 9 y SEQ ID Nº 10, SEQ ID Nº 11 y SEQ ID Nº 12, SEQ ID Nº 13 y SEQ ID Nº 14, SEQ ID Nº 15 y SEQ ID Nº 16, SEQ ID Nº 17 y SEQ ID Nº 18, SEQ ID Nº 19 y SEQ ID Nº 20, SEQ ID Nº 21 y SEQ ID Nº 22, SEQ ID Nº 23 y SEQ ID Nº 24, SEQ ID Nº 25 y SEQ ID Nº 26, SEQ ID Nº 27 y SEQ ID Nº 28, SEQ ID Nº 29 y SEQ ID Nº 30, SEQ ID Nº 31 y SEQ ID Nº 32, SEQ ID Nº 33 y SEQ ID Nº 34, SEQ ID Nº 39 y SEQ ID Nº 40, SEQ ID Nº 41 y SEQ ID Nº 42, SEQ ID Nº 43 y SEQ ID Nº 44.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14176717 | 2014-07-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR101185A1 true AR101185A1 (es) | 2016-11-30 |
Family
ID=51162604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP150102212A AR101185A1 (es) | 2014-07-11 | 2015-07-10 | Anticuerpos anti-factor v o factor v activado |
Country Status (3)
Country | Link |
---|---|
AR (1) | AR101185A1 (es) |
TW (1) | TW201617371A (es) |
WO (1) | WO2016005564A2 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019071116A1 (en) * | 2017-10-05 | 2019-04-11 | Epivax, Inc. | T REGULATORY LYMPHOCYTE EPITOPES |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT807691E (pt) * | 1994-02-14 | 2002-04-29 | Univ Leiden | Metodo para a pesquisa quanto a presenca de um defeito genetico associado a trombose e/ou fraca resposta anticoagulante a proteina c activada |
US20060014934A1 (en) * | 2004-05-18 | 2006-01-19 | Everse Stephen J | Crystal structure of factor Vai and method for identifying blood factor Va modulators |
US8236764B2 (en) * | 2006-02-23 | 2012-08-07 | The Children's Hospital Of Philadelphia | Methods for treating a hemostasis related disorder using activated forms of Factor V |
CA2666905A1 (en) * | 2006-10-16 | 2008-06-05 | Novelmed Therapeutics, Inc. | Method of inhibiting coagulation with human anti-factor va antibodies and use thereof |
-
2015
- 2015-07-10 AR ARP150102212A patent/AR101185A1/es unknown
- 2015-07-10 WO PCT/EP2015/065848 patent/WO2016005564A2/en active Application Filing
- 2015-07-13 TW TW104122521A patent/TW201617371A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2016005564A3 (en) | 2016-04-07 |
WO2016005564A2 (en) | 2016-01-14 |
TW201617371A (zh) | 2016-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201791961A1 (ru) | Антитела, специфичные к cd47 и pd-l1 | |
PH12021550023A1 (en) | Humanized anti-tau antibodies | |
PE20190737A1 (es) | Anticuerpos anti-cd27 | |
EA201690167A1 (ru) | Гуманизованные или химерные антитела к cd3 | |
MX366359B (es) | Anticuerpos humanizados contra la molecula de adhesion celular relacionada al antigeno carcinoembrionico 1 (ceacam1). | |
PE20151289A1 (es) | Anticuerpos que se unen al tl1a y sus usos | |
NI201700018A (es) | Anticuerpos anti-lag3 y fragmentos de unión a antígeno | |
EA201792589A1 (ru) | Антитела против cd123 и конъюгаты указанных антител | |
EA201890305A1 (ru) | Гуманизированные или химерные cd3-антитела | |
EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
CR20190009A (es) | Anticuerpos anti-pd-1, un método de producción y un método para su uso. | |
MX2018008934A (es) | Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso. | |
MX353278B (es) | Raton con cadena ligera comun. | |
AR102239A1 (es) | Anticuerpos anti-ox40 humanizados y sus usos | |
PE20160690A1 (es) | Anticuerpos anti-cd134 (ox40) humanizados y usos de los mismos | |
CO2019013669A2 (es) | Anticuerpos anti-garp-tgf-β | |
EA201791527A1 (ru) | Биспецифические антитела против плазменного калликреина и фактора xii | |
AR105267A1 (es) | Anticuerpos de unión a tau | |
CO2019007686A2 (es) | Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo | |
EA201990894A1 (ru) | Анти-pd-1/анти-her2 гетеродимерное биспецифическое антитело со структурой природного антитела и способ его получения | |
EA201892225A1 (ru) | АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ | |
EA201890340A1 (ru) | Моноклональное антитело-ингибитор фактора xiia | |
CO2017004753A2 (es) | Anticuerpos que se unen a ccr6 | |
PE20161404A1 (es) | Anticuerpos ang2 | |
PH12015501650A1 (en) | Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |